Yearly STL Archives: 2024

An Update on Current Clinical Management and Emerging Treatments in Hidradenitis Suppurativa

Explore current and emerging therapies for Hidradenitis Suppurativa (HS), a chronic, painful skin condition. This article reviews the challenges of HS treatment and introduces novel approaches including biologics like secukinumab and innovative therapies in clinical trials.

Overview of Dermatological Manifestations Associated with the COVID-19 Infection

Discover the diverse dermatological manifestations in COVID-19 patients, including chilblain-like lesions, maculopapular rashes, and necrosis, reflecting the virus's complex impacts beyond respiratory symptoms. This review highlights the need for further research into these skin conditions' pathogenesis and treatment.

Update on Drugs & Devices: March – April 2024

Update on Adalimumab-ryvk for SC injection (Simlandi®), B-Raf inhibitor gel (LUT014), Lifileucel tumorinfiltrating lymphocyte (TIL) suspension for IV use (Amtagvi™), Berdazimer topical gel, 10.3% (Zelsuvmi™), Artificial intelligencepowered skin cancer diagnostic tool (DermaSensor™), Smallpox vaccine (ACAM2000®), Oral brincidofovir (Tembexa®), Ritlecitinib tosylate capsules (Litfulo™), Ustekinumab biosimilar (Jamteki™).

Spesolimab, A Novel Interleukin-36 Inhibitor for Generalized Pustular Psoriasis Flares in Adult Patients

Explore the groundbreaking role of Spesolimab, a novel interleukin-36 inhibitor, in treating Generalized Pustular Psoriasis flares in adults. This article presents key findings from phase 1 and 2 clinical trials, emphasizing Spesolimab's effectiveness and safety.

1726 nm Lasers for the Treatment of Acne Vulgaris

Explore the efficacy of 1726 nm lasers, specifically AviClear and Accure systems, in treating moderate to severe acne vulgaris, offering a safe and effective alternative to systemic therapies.

Update on Drugs & Devices: January – February 2024

Update on Roflumilast foam, 0.3% (Zoryve®), Birch triterpenes gel (Filsuvez®), Rapamycin anhydrous gel, 3.9% (Qtorin™), Bimekizumab-bkzx for SC use (Bimzelx®), Secukinumab for SC use (Cosentyx®), and Ustekinumab-auub for SC/IV use (Wezlana™).

Real-World Insights from Atopic Dermatitis Patients Treated with Abrocitinib

This real-world case series intends to illustrate a variety of moderate-to-severe AD patient cases to help guide discussions around abrocitinib and describe its treatment strategies used by experts in the field.

POPULAR

Advertisement